Current low-level SARS-CoV-2 circulation, with 3.8% test positivity and just 0.3% of U.S. emergency visits attributed to COVID-19 as of mid-August 2026, underpins the 96% market-implied probability against a new coronavirus pandemic this year. Official surveillance from the CDC and WHO shows stable or modestly rising but very low activity across regions, consistent with endemic patterns rather than exponential growth or novel high-virulence emergence. Variants such as BA.3.2 continue to circulate without triggering PHEIC-level alerts or widespread severe outcomes. Traders assign near-certainty to “no” because no animal-origin spillover or immune-evasive strain has demonstrated sustained human-to-human transmission capable of overwhelming health systems. A realistic shift could occur if a new variant rapidly acquires both high transmissibility and increased virulence before updated vaccines or antivirals are deployed.